Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases, appointed William Kachioff as chief financial officer and James Vollins general counsel, chief compliance officer and corporate secretary.

Kachioff is experienced in corporate finance, investor relations, capital formation, corporate governance and manufacturing accounting and systems. He has more 30 years of life sciences industry experience and is currently a consulting CFO with Danforth Advisors, with whom Eiger has contracted for his services. He recently served as interim CFO at Aduro Biotech (now Chinook Therapeutics), a publicly traded, clinical-stage cancer immunotherapy company and previously served as CFO at GenomeDx Biosciences (now Veracyte) and Biocept, two providers of novel cancer diagnostic services. Prior to that, he was CFO at Althea Technologies (now Ajinomoto Bio-Pharma), a pharmaceutical contract manufacturer.

Vollins is an experienced public company, biotechnology, and healthcare compliance attorney with executive leadership experience and a focus on scaling high-quality biotech companies and best-in-class compliance programs. During his 30-year legal career, he has worked for several global biotechnology companies in roles of increasing responsibility. Prior to joining Eiger, Vollins was general counsel, chief compliance officer and corporate secretary at BioDelivery Sciences International, Inc. Before that, he was general counsel, chief compliance officer and corporate secretary at Bio Products Laboratory Ltd.

“We are excited to welcome two seasoned biotech executives to the Eiger executive team, both of whom have a proven track record of delivering results and creating significant shareholder value,” said David Apelian, interim CEO, Eiger. “Mr. Kachioff brings extensive financial and strategic expertise, combined with a deep knowledge of the biotechnology sector. Mr. Vollins’ extensive legal expertise and insight will be invaluable as we continue to advance our programs. Their appointments come during a pivotal time as we complete our program prioritization analyses to assess the most promising drivers of shareholder value. Both will be strong partners as we complete the transition and lead the company forward.”